| GA20299-1mg |
|
2022956-57-4 |
(Ser(PO₃H₂)²⁶²)-Tau Peptide (260-264) PAb Blocking
|
0 |
C20H36N5O13P |
|
|
|
| GA20299-005mg |
|
2022956-57-4 |
(Ser(PO₃H₂)²⁶²)-Tau Peptide (260-264) PAb Blocking
|
0 |
C20H36N5O13P |
|
|
|
| GA20298-1mg |
|
2022956-55-2 |
(Ser(PO₃H₂)²⁰²,Thr(PO₃H₂)²⁰⁵)-Tau Peptide (194-213)
|
0 |
C81H133N29O36P2 |
|
|
|
| GA20298-005mg |
|
2022956-55-2 |
(Ser(PO₃H₂)²⁰²,Thr(PO₃H₂)²⁰⁵)-Tau Peptide (194-213)
|
0 |
C81H133N29O36P2 |
|
|
|
| GA20297-1mg |
|
— |
(Ser(GlcNAc-β-D)²³⁶)-EMSY (230-240)
|
0 |
C56H97N13O21 |
|
|
|
| GA20297-005mg |
|
— |
(Ser(GlcNAc-β-D)²³⁶)-EMSY (230-240)
|
0 |
C56H97N13O21 |
|
|
|
| GA20296-5mg |
|
1926163-83-8 |
(Ser(Ac)⁴,D-Ser(tBu)⁶,Azagly¹⁰)-LHRH
|
0 |
C61H86N18O15 |
|
|
|
| GA20296-1mg |
|
1926163-83-8 |
(Ser(Ac)⁴,D-Ser(tBu)⁶,Azagly¹⁰)-LHRH
|
0 |
C61H86N18O15 |
|
|
|
| GA20295-1mg |
|
321974-76-9 |
(Ser(Ac)³)-Ghrelin (mouse, rat)
|
0 |
C141H233N45O42 |
|
|
|
| GA20295-005mg |
|
321974-76-9 |
(Ser(Ac)³)-Ghrelin (mouse, rat)
|
0 |
C141H233N45O42 |
|
|
|
| GA20294-100mg |
|
53632-49-8 |
(Sar¹,Thr⁸)-Angiotensin II
|
0 |
C44H69N13O11 |
|
|
|
| GA20294-25mg |
|
53632-49-8 |
(Sar¹,Thr⁸)-Angiotensin II
|
0 |
C44H69N13O11 |
|
|
|
| GA20293-25mg |
|
185461-45-4 |
(Sar¹,Ile⁴·⁸)-Angiotensin II
|
0 |
C43H75N13O9 |
|
|
|
| GA20293-5mg |
|
185461-45-4 |
(Sar¹,Ile⁴·⁸)-Angiotensin II
|
0 |
C43H75N13O9 |
|
|
|
| GA20292-100mg |
|
51887-62-8 |
(Sar¹,Gly⁸)-Angiotensin II
|
0 |
C42H65N13O10 |
|
|
|
| GA20292-25mg |
|
51887-62-8 |
(Sar¹,Gly⁸)-Angiotensin II
|
0 |
C42H65N13O10 |
|
|
|
| GA20291-100mg |
|
51833-69-3 |
|
0 |
C49H71N13O10 |
|
|
|
| GA20291-25mg |
|
51833-69-3 |
|
0 |
C49H71N13O10 |
|
|
|
| GA20290-25g |
|
90742-94-2 |
(S)-3-Isopropylamino-1,2-propanediol
|
0 |
C6H15NO2 |
|
|
|
| GA20290-5g |
|
90742-94-2 |
(S)-3-Isopropylamino-1,2-propanediol
|
0 |
C6H15NO2 |
|
|
|
